Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis (Q44276019)

1 December 2017

Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis (English)

1 reference

cost-effectiveness analysis

1 December 2017

1 reference

1 reference

11

Jaakko Tuomilehto

1 reference

1 December 2017

3

David Eddy

1 reference

1 December 2017

7

Edward Gregg

1 reference

1 December 2017

John Buse

5

0 references

M Sue Kirkman

9

object named as

M Sue Kirkman

1 reference

1 December 2017

Richard Kahn

1

1 reference

1 December 2017

Peter Alperin

2

1 reference

1 December 2017

Knut Borch-Johnsen

4

1 reference

1 December 2017

Justin Feigelman

6

1 reference

1 December 2017

Rury R Holman

8

1 reference

1 December 2017

Michael Stern

10

1 reference

1 December 2017

Nick J Wareham

12

1 reference

1 December 2017

language of work or name

English

0 references

publication date

29 March 2010

1 reference

1 December 2017

1 reference

1 December 2017

375

1 reference

1 December 2017

9723

1 reference

1 December 2017

1365-1374

1 reference

Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002.

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the hoorn screening study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Screening for type 2 diabetes mellitus in adults: U.S. Preventive Services Task Force recommendation statement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Population screening for diabetes mellitus. Professional Advisory Committee of the British Diabetic Association

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Estimating the microvascular benefits of screening for type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Screening for type 2 diabetes mellitus: a cost-effectiveness analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Screening for Type 2 diabetes mellitus: a decision analytic approach.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

What determines the cost-effectiveness of diabetes screening?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

A computer simulation model for cost-effectiveness analysis of mass screening for Type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Cost-effectiveness analysis of different screening procedures for type 2 diabetes: the KORA Survey 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Validation of the Archimedes Diabetes Model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Archimedes: a new model for simulating health care systems--the mathematical formulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Archimedes: a trial-validated model of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

The impact of prevention on reducing the burden of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Preference-Based EQ-5D index scores for chronic conditions in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Valuing health-related quality of life in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Effects of intensive glucose lowering in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Impact of diabetes screening on quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2962162-0

7 January 2021

10.1016/S0140-6736(09)62162-0

Identifiers

DOI

1 reference

1 December 2017

1 reference